Skip to content
10-Q

Quarterly Report

Nautilus Biotechnology, Inc. NAUT

0001808805-24-000072

← back to feed
Filed
Oct 29, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 24, 2024 125.56M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $4.41M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $19.4M
Current Liabilities Q3 2024 · Sep 30, 2024 $8.66M
Current Liabilities Q3 2024 · Dec 31, 2023 $9.12M
Total Liabilities Q3 2024 · Sep 30, 2024 $36.27M
Total Liabilities Q3 2024 · Dec 31, 2023 $40.21M
Current Assets Q3 2024 · Sep 30, 2024 $144.21M
Current Assets Q3 2024 · Dec 31, 2023 $176.84M
Total Assets Q3 2024 · Sep 30, 2024 $259.7M
Total Assets Q3 2024 · Dec 31, 2023 $305.57M
Shares Diluted Q3 2024 · Sep 30, 2023 124.93M sh
Shares Diluted Q3 2024 · Sep 30, 2023 124.9M sh
Capex Q3 2024 · Sep 30, 2023 $2.03M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$37.81M
Stockholders Equity Q3 2024 · Sep 30, 2023 $277.27M
Stockholders Equity Q3 2024 · Jun 30, 2023 $289.67M
Stockholders Equity Q3 2024 · Dec 31, 2022 $314.92M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.13
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.37
Eps Basic Q3 2024 · Sep 30, 2023 −$0.13
Eps Basic Q3 2024 · Sep 30, 2023 −$0.37
Rd Expense Q3 2024 · Sep 30, 2023 $12M
Rd Expense Q3 2024 · Sep 30, 2023 $34.79M
Net Income Q3 2024 · Sep 30, 2023 −$15.88M
Net Income Q3 2024 · Sep 30, 2023 −$46.65M